Compare WABC & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WABC | NTLA |
|---|---|---|
| Founded | 1972 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 1994 | 2016 |
| Metric | WABC | NTLA |
|---|---|---|
| Price | $51.22 | $15.45 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 18 |
| Target Price | ★ $52.50 | $18.34 |
| AVG Volume (30 Days) | 140.8K | ★ 3.0M |
| Earning Date | 04-16-2026 | 05-21-2026 |
| Dividend Yield | ★ 3.63% | N/A |
| EPS Growth | N/A | ★ 27.43 |
| EPS | ★ 3.40 | N/A |
| Revenue | N/A | ★ $67,671,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $57.37 |
| P/E Ratio | $14.87 | ★ N/A |
| Revenue Growth | N/A | ★ 16.92 |
| 52 Week Low | $42.00 | $5.90 |
| 52 Week High | $53.48 | $28.24 |
| Indicator | WABC | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 66.06 |
| Support Level | $46.33 | $10.44 |
| Resistance Level | $52.36 | $17.09 |
| Average True Range (ATR) | 1.45 | 0.93 |
| MACD | -0.23 | 0.20 |
| Stochastic Oscillator | 38.48 | 94.65 |
Westamerica Bancorp is based in San Rafael, California. Westamerica Bancorporation runs a regional community bank and has approximately $7.5 billion in assets. The banks' net revenue is generated by net interest income. Deposit service charges make up the noninterest income sources. The bank focuses mostly on commercial clients, such as smaller businesses. Its footprint encompasses central and northern California, extending north of San Francisco to Mendocino and Lake counties, south to Kern County in central California and all the way east to Nevada County.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.